Serina Therapeutics, Inc.SERNYSE
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank38
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P38
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q3 2025-2.67%
Q2 202513.23%
Q1 20255.82%
Q4 2024-54.93%
Q3 202463.02%
Q2 2024-407.86%
Q1 2024-1403.31%
Q4 2023111.82%
Q3 2023-18.52%
Q2 2023-21.86%
Q1 202346.33%
Q4 2022-6.88%
Q3 202229.21%
Q2 2022-6.72%
Q1 20220.67%
Q4 202112.58%
Q3 2021-11.22%
Q2 202135.59%
Q1 2021-62.35%
Q4 202014.24%
Q3 202015.82%
Q2 2020-8.72%
Q1 202014.39%
Q4 2019-1.64%
Q3 201914.03%
Q2 2019-5.39%
Q1 20190.00%
Q4 20180.00%
Q3 201817.49%
Q2 2018-7.78%
Q1 20180.00%
Q4 20170.00%
Q3 201769.40%
Q2 2017-10.86%
Q1 20170.00%